Goldman Sachs Group Inc Acquires 500,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Goldman Sachs Group Inc bought 500,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the insider owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. This trade represents a 19.84% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Goldman Sachs Group Inc also recently made the following trade(s):

• On Wednesday, August 5th, Goldman Sachs Group Inc sold 105,807 shares of Attovia Therapeutics stock. The stock was sold at an average price of $21.28, for a total value of $2,251,572.96.
• On Wednesday, August 5th, Goldman Sachs Group Inc purchased 85,000 shares of Attovia Therapeutics stock. The shares were bought at an average cost of $21.00 per share, with a total value of $1,785,000.00.

Attovia Therapeutics Trading Up 6.2%

NASDAQ:ATTO traded up $1.12 during midday trading on Thursday, reaching $19.18. The stock had a trading volume of 406,507 shares, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 12-month low of $16.15 and a 12-month high of $22.79.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. increased its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.